16.9 C
New York
Wednesday, May 25, 2022

Positive Preliminary GEN-011 Data: Genocea Biosciences, Inc. (GNCA) Stock Rebounds Aftermarket Following a Dive in Regular Trading.

Genocea Biosciences, Inc. (GNCA) develops transformative immunotherapeutics for cancer patients with its exclusive ATLAS platform. Its shares price plunged deep by 69.2% to remain at $0.40 at the closing of Friday’s regular trading. The price gained pace by 23.2% in the aftermarket session. The current stock price as of the writing stands at $0.49.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


GNCA: Recent Developments

GNCA stated to present the clinical data of its pipeline candidates at the 2022 Annual Meeting of the American Association for Cancer Research. The company will present hopeful preliminary results from the TiTAN clinical studies for its NPT therapy pipeline candidate GEN-011 along with the accomplishment of GEN-011 production, and \ preclinical data on Inhibigens.

The TiTAN studies are in Phase 1/2 clinical trials and it brings into consideration the safety, tolerability, and proliferation of GEN-011 used to treat refractory solid tumors patients. The preliminary findings showed its anti-tumor activity despite the minor intensity regimens and severely pretreated tumors.

GNCA: Industry Outlook

Biotechnology stocks are one of the most volatile areas of the market as they were the biggest gainers during the pandemic but not performing well now. The SPDR S&P Biotech ETF tracks the full S&P biotech industry, dipped by 47% in comparison to its peak in initial February 2021.  Investors should choose a biotech stock wisely, as many of the stocks are one FDA approval away from achievement or failure. Therefore, the investors should turn their heads toward the companies that offer a strong pipeline of new drugs and an existing successful drugs line to keep their business financially stable.

GNCA: Company Outlook

For the fourth quarter of 2021, GNCA announced a diluted net loss per share of -$0.19 and -$0.48 for the full fiscal year 2021. The company’s existing cash is enough to support its current operations through Q3 2022, however, the company has strategic plans to extend its operations into 2023. The company also provided the details regarding the participation of its Executive management at various investor and healthcare conferences during the months of January-March, 2022.


The price of GNCA shares fell by more than 80% in the past year. Its current market position is strong as the company dived during Friday’s trading following the release of positive GEN-11 preliminary data. Its price rebounded in the after-hours after the investors placed their trust in the preliminary findings.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles